GLP-1 Receptor Agonists: Everything You Need to Know in 2026

What GLP-1 Receptor Agonists Actually Are

If you have been anywhere near a news cycle, a gym conversation, or a Thanksgiving dinner table in the last three years, you have heard about these drugs. Ozempic. Wegovy. Mounjaro. Zepbound. The names are everywhere. But a surprising number of people -- including some who are already taking them -- do not fully understand what these medications are or how they work.

Let us fix that.

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body naturally produces in the gut after you eat. Your intestinal L-cells release it, and it does several important things: it tells your pancreas to make insulin, it tells your liver to ease off glucose production, and it sends signals to your brain that you are full. The problem with natural GLP-1 is that it breaks down in your bloodstream in about two minutes. It works fast, and it disappears fast.

GLP-1 receptor agonists are synthetic versions of this hormone, engineered to last much longer in the body. Semaglutide, for example, has a half-life of roughly seven days. That means a single weekly injection keeps those fullness and metabolic signals firing around the clock, rather than for the two minutes your natural GLP-1 lasts after a meal.

These drugs were originally developed for type 2 diabetes management. Researchers noticed that patients on GLP-1 agonists were also losing significant amounts of weight -- far more than expected from blood sugar control alone. That observation led to dedicated weight loss trials, which led to FDA approvals specifically for chronic weight management. The rest is pharmaceutical history.

How They Work: The Mechanism of Action

Understanding the pharmacology here matters because it explains both why these drugs work so well and why the side effects exist. GLP-1 receptor agonists operate through four primary pathways:

1. Appetite Suppression via the Brain

This is the big one for weight loss. GLP-1 receptors exist in the hypothalamus and brainstem -- the regions responsible for appetite regulation and food reward. When semaglutide or tirzepatide activates these receptors, it reduces hunger signals and, critically, reduces the reward response you get from eating. People on these medications frequently describe food as just being less interesting. The constant background hum of "I want to eat" gets turned down.

This is a meaningful distinction from willpower-based dieting. These drugs change the neurological signaling around food. You are not white-knuckling your way past cravings. The cravings are genuinely reduced.

2. Delayed Gastric Emptying

GLP-1 agonists slow down how quickly food moves from your stomach into your small intestine. Your stomach stays fuller longer, which reinforces the feeling of satiety after meals. This mechanism also partially explains one of the most common side effects -- nausea -- which we will get to later.

3. Insulin Regulation

These medications enhance insulin secretion in a glucose-dependent manner. This means they primarily boost insulin when blood sugar is elevated, which substantially lowers the risk of hypoglycemia compared to drugs like sulfonylureas that stimulate insulin regardless of blood sugar levels. For people with type 2 diabetes or insulin resistance, this mechanism improves glycemic control significantly.

4. Glucagon Suppression

GLP-1 agonists reduce the secretion of glucagon, a hormone that tells your liver to dump glucose into the bloodstream. Less glucagon means less hepatic glucose output, which helps keep blood sugar levels more stable throughout the day.

Tirzepatide adds a fifth pathway -- it is a dual GIP/GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone. By activating both receptor types, tirzepatide appears to produce more potent metabolic effects and greater weight loss than GLP-1-only drugs. The exact mechanism of how GIP receptor activation contributes to weight loss is still being studied, but the clinical results speak for themselves.

The Big Three: Semaglutide, Tirzepatide, and Liraglutide

There are three GLP-1 receptor agonists that dominate the conversation in 2026. Each has its own profile, history, and place in the treatment landscape.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide is the drug that started the cultural phenomenon. Novo Nordisk developed it, and it comes in three branded versions. Ozempic (injectable, approved for type 2 diabetes in December 2017) operates at doses of 0.5mg, 1mg, and 2mg weekly. Wegovy (injectable, approved for chronic weight management in June 2021) is the same molecule at a higher dose of 2.4mg weekly. Rybelsus is an oral tablet version approved for diabetes, dosed at 7mg or 14mg daily.

Wegovy's FDA approval was based on the STEP trial program, which we will dig into shortly. It is approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). In late 2022, the FDA expanded approval to include adolescents aged 12 and older meeting weight criteria.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is Eli Lilly's entry and the newer, more aggressive player. Mounjaro was approved for type 2 diabetes in May 2022. Zepbound was approved for chronic weight management in November 2023. Tirzepatide is a dual GIP/GLP-1 receptor agonist -- the only one in its class with FDA approval -- and is dosed at 5mg, 10mg, or 15mg weekly by injection.

The SURMOUNT trial data for tirzepatide showed weight loss numbers that exceeded what semaglutide achieved in the STEP trials, making it arguably the most potent pharmaceutical weight loss tool available. We will break down those numbers in the next section.

Liraglutide (Saxenda / Victoza)

Liraglutide is the original, and at this point, the least popular option for weight loss. Victoza was approved for type 2 diabetes in 2010. Saxenda was approved for weight management in December 2014 at a dose of 3mg daily. The critical difference: liraglutide requires daily injections rather than weekly, and the weight loss results are more modest than either semaglutide or tirzepatide.

Saxenda still has a role for patients who cannot tolerate semaglutide or tirzepatide, or for those who prefer to start with a lower-potency option. But in terms of efficacy and convenience, it has been surpassed by the newer drugs.

The Clinical Trial Data You Should Know

We are going to give you the actual numbers from the major clinical trials because that is what HonestLifter does. These are the studies that the FDA used to make approval decisions, and they are the most reliable data points we have.

The STEP Trials (Semaglutide / Wegovy)

The STEP (Semaglutide Treatment Effect in People with obesity) program included four major trials:

STEP 1 (Wilding et al., 2021, NEJM): 1,961 adults with BMI 30+ (or 27+ with comorbidities) without type 2 diabetes. Semaglutide 2.4mg weekly vs. placebo, both with lifestyle intervention, for 68 weeks. The semaglutide group lost an average of 14.9% of body weight compared to 2.4% in the placebo group. More than one-third of participants achieved 20% or greater weight loss. This was the landmark trial that changed the conversation.

STEP 2: Focused on adults with type 2 diabetes and overweight/obesity. Semaglutide 2.4mg produced 9.6% body weight loss vs. 3.4% with placebo over 68 weeks. The lower numbers compared to STEP 1 are consistent with what we see across weight loss interventions -- people with type 2 diabetes typically lose less weight, partly due to insulin's anabolic effects.

STEP 3: Combined semaglutide with intensive behavioral therapy (30 counseling sessions over 68 weeks). Average weight loss was 16.0% with semaglutide vs. 5.7% with placebo. This trial demonstrated that combining medication with structured behavioral support produces the best results -- a finding that should surprise absolutely nobody.

STEP 4: This was the withdrawal study. Participants took semaglutide for 20 weeks, and then half were switched to placebo for an additional 48 weeks. Those who continued semaglutide lost an additional 7.9% of body weight. Those switched to placebo regained 6.9% of the weight they had initially lost. This trial is the most important one for understanding the long-term trajectory of GLP-1 use.

The SURMOUNT Trials (Tirzepatide / Zepbound)

SURMOUNT-1 (Jastreboff et al., 2022, NEJM): 2,539 adults with BMI 30+ (or 27+ with comorbidities) without type 2 diabetes. Three tirzepatide doses tested (5mg, 10mg, 15mg) vs. placebo for 72 weeks. Results by dose:

• 5mg: 15.0% body weight loss (vs. 3.1% placebo)
• 10mg: 19.5% body weight loss
• 15mg: 20.9% body weight loss

At the highest dose, more than one-third of participants lost 25% or more of their body weight. More than half lost at least 20%. These numbers were substantially higher than what STEP 1 showed for semaglutide, and they set a new benchmark for pharmaceutical weight loss.

SURMOUNT-2: Tested tirzepatide in adults with type 2 diabetes and BMI 27+. The 15mg dose produced 14.7% body weight loss vs. 3.2% with placebo over 72 weeks. Again, the diabetes population showed lower absolute weight loss, but the numbers were still impressive compared to semaglutide's STEP 2 results.

SURMOUNT-3 and SURMOUNT-4 continued to build the evidence base. SURMOUNT-4 was the withdrawal design, and it showed a familiar pattern -- participants who stayed on tirzepatide continued losing weight, while those switched to placebo regained roughly half of what they had lost during the initial treatment period.

The SELECT Trial (Cardiovascular Outcomes)

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) deserves its own mention. Published in 2023, this was a cardiovascular outcomes trial with over 17,600 participants aged 45+ with existing cardiovascular disease and BMI 27+ (without diabetes). Semaglutide 2.4mg weekly reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo.

This trial was a game-changer for insurance coverage discussions because it demonstrated that semaglutide has benefits beyond just weight loss. It reduces hard cardiovascular endpoints in an at-risk population. That is the kind of data that shifts payer decisions.

Head-to-Head Comparison Table

Here is a side-by-side look at the three major GLP-1 receptor agonists available in 2026:

A few things jump out from this comparison. Tirzepatide produces the highest average weight loss, likely because the dual GIP/GLP-1 mechanism provides additive effects. It also appears to have a somewhat lower nausea rate than semaglutide at comparable efficacy levels, though direct head-to-head data between the two drugs is limited. Liraglutide is the least effective of the three and requires daily injections, which makes it the least convenient option. Its main advantage at this point is that it has the longest post-marketing safety track record, having been on the market since 2010.

Side Effects: What the Data Actually Shows

Let us be direct about this. GLP-1 receptor agonists cause side effects. The question is which ones, how often, and how serious they are. We are going to separate the common and expected from the rare and concerning.

Common Side Effects (Gastrointestinal)

GI side effects are the most frequent complaint across all GLP-1 agonists. From the STEP and SURMOUNT trial data:

• Nausea: Reported by 44% of semaglutide users and 24-33% of tirzepatide users (dose-dependent) in clinical trials. Nausea is typically worst during dose escalation and tends to improve over weeks 4-8 as the body adjusts. Most prescribers use a gradual dose titration protocol specifically to minimize this.
• Diarrhea: Reported by about 30% of semaglutide users and 17-23% of tirzepatide users.
• Vomiting: About 24% for semaglutide and 6-13% for tirzepatide.
• Constipation: Around 24% for semaglutide and 6-11% for tirzepatide.

These GI side effects are a direct consequence of the mechanism of action. Slowed gastric emptying means food sits in your stomach longer, which causes nausea, especially if you eat too much or too fast. The good news: most of these side effects are mild to moderate, and they improve with time. The bad news: for a meaningful minority of users, they persist long enough to prompt discontinuation. In STEP 1, about 7% of semaglutide users dropped out due to GI side effects.

Gastroparesis Concerns

You may have seen headlines about GLP-1 agonists causing gastroparesis (stomach paralysis). Here is what the evidence actually shows.

GLP-1 agonists slow gastric emptying. That is part of how they work. In most people, this slowing is moderate and manageable. However, there have been reports of severe, prolonged gastroparesis in some patients, including cases that persisted after stopping the medication. The FDA updated the labeling to include gastroparesis-like symptoms as a known adverse reaction.

The absolute risk appears to be low. A 2023 study published in JAMA found that GLP-1 agonist use was associated with increased risk of pancreatitis, bowel obstruction, and gastroparesis compared to bupropion-naltrexone, but the absolute rates were still small. If you have a history of gastroparesis or severe GI motility disorders, these medications may not be appropriate for you, and that is a conversation for your prescriber.

Pancreatitis

Acute pancreatitis has been reported in clinical trials and post-marketing data for GLP-1 agonists. In the STEP trials, pancreatitis events were rare but did occur. The causal relationship is still debated -- obesity itself is a risk factor for pancreatitis, which makes it difficult to separate the drug effect from the baseline population risk.

The FDA labeling for all GLP-1 agonists includes pancreatitis as a warning. If you develop severe abdominal pain that does not resolve, contact your doctor immediately. Patients with a history of pancreatitis should exercise caution with these medications.

Thyroid Tumors

Semaglutide and liraglutide both carry a boxed warning about thyroid C-cell tumors. This comes from rodent studies where both drugs caused dose-dependent increases in thyroid medullary carcinoma in rats and mice. The relevance to humans is unclear -- rodent thyroid C-cells express far more GLP-1 receptors than human thyroid C-cells, and no causal link to thyroid cancer has been established in human studies to date.

That said, GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). This is a standard screening question before prescribing.

Gallbladder Issues

Rapid weight loss from any cause increases the risk of gallstones and cholecystitis, and GLP-1 agonists are no exception. In the STEP trials, gallbladder-related events occurred in about 2.6% of semaglutide users vs. 1.2% on placebo. If you have a history of gallbladder disease, your prescriber should be aware.

Muscle Loss

We covered this in detail in our semaglutide and fitness article, but it bears repeating here. STEP 1 data showed that approximately 39% of weight lost with semaglutide was lean body mass. This is higher than the typical 25% seen with well-managed diet and exercise. The trial participants were not doing resistance training or eating optimized protein, which means the number is likely improvable with proper interventions. But it is a real concern, especially for people who care about body composition and long-term metabolic health.

The Cost Landscape in 2026

Money matters. These are expensive medications, and the cost landscape has been shifting throughout 2025 and into 2026. Here is where things stand.

List Prices

The list price for Wegovy (semaglutide 2.4mg) has been in the range of $1,300 to $1,400 per month. Eli Lilly priced Zepbound (tirzepatide) somewhat lower at launch, around $1,000 to $1,100 per month, which was a deliberate competitive move. Saxenda (liraglutide) sits in a similar range to Wegovy at roughly $1,300 to $1,400 monthly.

In early 2025, Eli Lilly introduced LillyDirect, a direct-to-patient program offering single-dose vials of Zepbound at reduced prices for patients without insurance coverage. The single-dose vials were priced starting around $399 per month for the lowest dose and up to $549 for the highest, representing a significant reduction from the list price. Novo Nordisk has made similar moves with savings programs and direct distribution channels.

Insurance Coverage

Insurance coverage remains the single biggest variable in what you will actually pay. The landscape breaks down roughly like this:

• Type 2 diabetes indication: Most commercial insurance plans cover Ozempic and Mounjaro for diabetes management with standard specialty pharmacy copays. Coverage here is relatively straightforward.
• Obesity/weight management indication: Coverage is inconsistent. Some commercial plans cover Wegovy or Zepbound for obesity, often with prior authorization requirements (documented BMI, failed lifestyle interventions). Many plans still exclude weight management medications entirely. Medicare Part D historically excluded obesity drugs, though the TREAT Act and similar legislation have been pushing to change this.
• Employer plans: Increasingly covering GLP-1s for weight management as employers recognize that obesity treatment reduces downstream healthcare costs. But coverage varies enormously by employer.

The SELECT trial cardiovascular data has been a significant lever for expanding insurance coverage. When a drug demonstrates a 20% reduction in heart attacks and strokes, payers have a harder time justifying exclusion.

What You Will Actually Pay

If you have insurance coverage with a reasonable copay, you might pay $25 to $150 per month. If you are using manufacturer savings cards (which both Novo Nordisk and Eli Lilly offer), commercially insured patients can often get their costs down to the $25 to $50 range for a limited period.

If you are paying entirely out of pocket, plan for $800 to $1,400 per month depending on the drug and source. Over a typical 12 to 18 month treatment course, that is $9,600 to $25,200. That is a material financial decision for most people.

The Compounding Pharmacy Controversy

This is one of the most contentious topics in the GLP-1 space, and it deserves a careful breakdown.

What Compounding Is

Compounding pharmacies create customized medications based on a physician's prescription. Under federal law (specifically section 503A of the Federal Food, Drug, and Cosmetic Act), compounding pharmacies can produce copies of commercially available drugs when those drugs are on the FDA's drug shortage list. Semaglutide was on that list for an extended period due to massive demand outstripping Novo Nordisk's manufacturing capacity.

During the shortage, compounding pharmacies began producing semaglutide formulations at significantly lower prices -- often $200 to $500 per month compared to $1,300+ for brand-name Wegovy. This opened access for millions of people who could not afford the brand-name drug or did not have insurance coverage.

The FDA's Position

In late 2024, the FDA declared that the semaglutide shortage had been resolved, which legally should have ended compounding pharmacies' authority to produce copies. However, this triggered immediate legal challenges. Several compounding pharmacy associations filed suit, arguing that the shortage was not truly resolved and that removing compounded semaglutide would harm patients who depended on affordable access. Courts issued injunctions that temporarily allowed compounding to continue while litigation proceeded.

As of mid-2026, the legal situation remains fluid. Some compounding pharmacies continue to produce semaglutide products under various legal frameworks, while others have shifted to different formulations (such as semaglutide salts rather than the base form) to argue they are producing different compounds entirely. The FDA has pushed back on this, arguing that these salt forms are essentially the same drug and should not be compounded when the branded version is available.

Quality and Safety Concerns

The FDA has raised legitimate safety concerns about some compounded GLP-1 products. Issues identified through inspections and adverse event reports include:

• Sterility failures in compounded injectables
• Inaccurate dosing (some products tested contained more or less active ingredient than labeled)
• Contamination with particulate matter
• Products sold as semaglutide that contained different or additional active ingredients

These are serious issues. Injectable medications that are not properly compounded can cause infections, allergic reactions, or unpredictable dosing effects.

That said, reputable 503B outsourcing facilities -- which are subject to FDA inspection and cGMP (current Good Manufacturing Practice) requirements -- produce high-quality compounded medications. The problem is that not all compounding pharmacies operate at this standard, and it can be difficult for patients to distinguish between a well-regulated facility and one cutting corners.

Our Take

The compounding situation highlights a genuine tension between drug pricing, patient access, and safety standards. Brand-name GLP-1 agonists are priced beyond what many people can afford. Compounded versions expanded access dramatically. But the quality control concerns are real and documented.

If you are considering compounded semaglutide, look for a 503B outsourcing facility that is registered with the FDA and has passed recent inspections. Ask for certificates of analysis for their product. Work with a legitimate prescriber who monitors your treatment. And understand that you are accepting a different risk profile than with the brand-name product.

Who These Medications Are Actually For

Based on the clinical evidence, FDA-approved indications, and risk-benefit analysis, here is who stands to benefit most from GLP-1 receptor agonists:

The strongest case for these medications:

• Adults with a BMI of 30 or greater who have not achieved sufficient weight loss through diet and exercise alone. This is the core FDA indication and the population where the benefit-to-risk ratio is clearest.
• Adults with a BMI of 27 or greater with at least one weight-related comorbidity -- type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The SELECT trial data makes the case especially strong for those with existing cardiovascular disease.
• People with type 2 diabetes where GLP-1 agonists serve double duty: improving glycemic control and reducing body weight. For this population, the drugs were originally designed and have the deepest evidence base.

Where the case gets weaker:

• People who are mildly overweight (BMI 25-27) without comorbidities. The clinical trials were not designed for this population. The side effect burden may not be justified when lifestyle modifications -- consistent exercise like walking, adequate protein intake, and sustained caloric management -- can achieve the needed weight loss.
• People at a normal weight seeking cosmetic fat loss. Using a drug designed for clinical obesity to lose the last 10 pounds for aesthetic reasons carries a meaningfully different risk-benefit ratio. The side effects and unknowns are the same regardless of your starting weight. The potential benefit is smaller.
• People who have not made genuine lifestyle attempts. GLP-1 agonists work best when combined with dietary changes and exercise. If you start the medication without addressing the habits that contributed to weight gain, you are setting yourself up for the full weight regain pattern when you eventually stop.

We are not here to tell anyone what to do with their body or their healthcare decisions. But we are here to make sure you have the information to make those decisions with clear eyes. If you have a BMI of 35 and hypertension and you have been fighting your weight for years, these drugs could genuinely improve your health and your life. If you are at 22% body fat and want to see your abs for summer, the calculus is very different.

The Weight Regain Problem

This is the part of the GLP-1 conversation that does not get enough honest attention. So let us be blunt about it.

The data from STEP 4 (the semaglutide withdrawal trial) showed that participants who stopped the medication regained approximately two-thirds of their lost weight within one year. SURMOUNT-4 showed a similar pattern for tirzepatide. Hunger levels returned to pre-treatment baselines. Metabolic improvements reversed in proportion to weight regained.

This is not the medication failing. This is the medication working exactly as designed -- and then being removed. GLP-1 agonists manage obesity the same way antihypertensives manage blood pressure or statins manage cholesterol. They work while you take them. Stop taking them, and the underlying condition reasserts itself.

The practical implications of this are significant:

• Many patients will need to stay on these medications long-term. The medical community is increasingly treating obesity as a chronic condition requiring ongoing pharmacotherapy, similar to diabetes or hypertension. For patients with severe obesity and comorbidities, lifelong treatment may be the most medically appropriate approach.
• The financial commitment extends accordingly. If you need to stay on the medication indefinitely, the cost calculation changes dramatically. $1,000 per month for 12 months is a lot. $1,000 per month for 20 years is a fundamentally different financial proposition.
• Building sustainable habits while on the medication is critical. Whether you plan to stay on the drug or eventually come off, you need to be building the exercise and nutrition habits that will support your health regardless. The medication should be a tool that makes behavior change easier, not a replacement for it.

GLP-1s and Fitness: What You Need to Know

We wrote an entire dedicated article on semaglutide and fitness that covers training adjustments, nutrition strategies, and the muscle preservation question in much more depth. Here is the condensed version.

Resistance Training Is Essential

If you are on a GLP-1 agonist and you are not lifting weights, you are almost certainly losing more muscle than you need to. The STEP 1 lean mass loss data (39% of weight lost was lean mass) came from a population that was not resistance training. Structured resistance training is the single most powerful tool for preserving muscle during any weight loss, and that includes medication-assisted weight loss.

Three to four sessions per week of compound-heavy resistance training (squats, deadlifts, bench press, rows, overhead press) with progressively challenging loads is the target. You do not need a complicated program. You need consistency with basic heavy lifts.

Protein Intake Is Non-Negotiable

One of the biggest challenges on a GLP-1 agonist is getting enough protein when your appetite is suppressed. Many users report food becoming genuinely uninteresting, which makes it easy to undereat protein. Aim for 0.7 to 1.0 grams per pound of body weight daily (or use target body weight if you are significantly overweight). Protein shakes, Greek yogurt, and other high-protein convenience foods become strategically important when eating feels like a chore.

Do Not Let Calories Drop Too Low

Some GLP-1 users, excited by rapid scale movement, allow their intake to fall below 800 or even 600 calories per day. This accelerates muscle loss, tanks your energy, disrupts your hormones, and compromises micronutrient status. A moderate deficit of 500 to 750 calories below maintenance is sustainable and protective. If the medication is suppressing your appetite below that threshold, you need to make a conscious effort to eat more. Track your intake, at least roughly, to make sure you are not running on fumes.

The Bottom Line

GLP-1 receptor agonists are the most significant development in obesity treatment in decades. That is not hype. The clinical trial data is robust, the weight loss results are dramatic, and the cardiovascular benefits (at least for semaglutide) are now supported by hard outcomes data from SELECT.

Here is what we think you should walk away understanding:

1. Tirzepatide (Zepbound) produces the most weight loss at ~21% of body weight at the highest dose, followed by semaglutide (Wegovy) at ~15%, and liraglutide (Saxenda) at ~5-8%. If maximum weight loss is the goal and your prescriber agrees, tirzepatide is the strongest option available.
2. Side effects are real and common. Nausea, vomiting, diarrhea, and constipation affect a large percentage of users, especially during dose escalation. Most side effects improve with time, but roughly 5-7% of trial participants discontinued due to adverse effects. Rare but serious concerns include gastroparesis, pancreatitis, and gallbladder disease.
3. These medications manage obesity -- they do not cure it. Stopping the medication leads to significant weight regain in most people. Plan accordingly. You may need long-term treatment, and the financial implications of that are substantial.
4. The cost barrier is still significant. Without insurance, expect $800 to $1,400 per month. Insurance coverage is improving but remains inconsistent, especially for weight management (as opposed to diabetes) indications. Compounded options exist at lower cost but come with quality control considerations.
5. Resistance training and adequate protein intake are essential companions to any GLP-1 agonist if you care about your body composition. The muscle loss data from clinical trials is concerning, but those trials did not include structured exercise or protein optimization. Take this seriously.
6. These medications are most appropriate for people with clinical obesity or obesity-related health conditions. Using them for mild cosmetic weight loss carries the same side effect risks with a smaller potential benefit. The risk-benefit math changes depending on your starting point.
7. Talk to an actual doctor. Not a telehealth app that will prescribe to anyone with a credit card. Not a fitness influencer with opinions. A healthcare provider who can evaluate your medical history, screen for contraindications, monitor your progress, and adjust your treatment as needed.

The GLP-1 revolution is real, and it is helping millions of people improve their health in ways that were not possible five years ago. These drugs deserve to be understood clearly -- their strengths, their limitations, their costs, and their trade-offs. That is what we have tried to do here.

Your health decisions are yours. We just want to make sure you are making them with good information.